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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the effects of betahistine in patients with subjective idiopathic tinnitus.
B A C K G R O U N D
This is a new protocol for a new Cochrane Review. The ’Descrip-
tion of the condition’ and ’Diagnosis and clinical management
of tinnitus’ sections are based on the Cochrane Review ’Amplifi-
cation with hearing aids for patients with tinnitus and co-exist-
ing hearing loss’ (Hoare 2014). Other sections are based on the
Cochrane protocol ’Betahistine forMénière’s disease or syndrome’
(van Esch 2018). They are both reproduced with permission.
Tinnitus is defined as the perception of sound in the absence of
an external source (Jastreboff 2004). It is typically described by
those who experience it as a ringing, hissing, buzzing or whoosh-
ing sound and is thought to result from abnormal neural activity
at some point or points in the auditory pathway, which is erro-
neously interpreted by the brain as sound. Tinnitus can be either
objective or subjective. Objective tinnitus refers to the perception
of sound that can also be heard by the examiner and is usually due
to turbulent blood flow or muscular contraction (Roberts 2010).
Most commonly, however, tinnitus is subjective; the sound is only
heard by the person experiencing it and no source of the sound is
identified (Jastreboff 1988).
Tinnitus affects between 5% and 43% of the general population
and prevalence increases with age (McCormack 2016). It can be
experienced acutely, recovering spontaneously within minutes to
weeks, but is considered chronic and unlikely to resolve sponta-
neously when experienced for more than three months (Gallus
2015; Hall 2011).
For many people, tinnitus is persistent and troublesome, and has
disabling effects such as insomnia, difficulty concentrating, dif-
ficulties in communication and social interaction, and negative
emotional responses such as anxiety and depression (Hall 2018).
In approximately 90% of cases chronic subjective tinnitus is co-
morbid with some degree of hearing loss, which may confound
these disabling effects (Fowler 1944; Sanchez 2002). Nevertheless,
the association between hearing loss and tinnitus is not simple or
straightforward; not all people with hearing loss experience tin-
nitus, and conversely some people with clinically normal hearing
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have tinnitus (Baguley 2013). It has been reported that 40% of
patients are unable to identify what health condition is associated
with their tinnitus onset, i.e. the tinnitus is idiopathic (Henry
2005).
Description of the condition
Diagnosis and clinical management of tinnitus
There is no standard procedure for the diagnosis ormanagement of
tinnitus. Practice guidelines and the approaches described in stud-
ies of usual clinical practice typically reflect differences between
the clinical specialities of the authors or differences in the clinical
specialities charged with meeting tinnitus patients’ needs (medi-
cal, audiology/hearing therapy, clinical psychology, psychiatry), or
the available resources of a particular country or region (access to
clinicians or devices, for example) (Biesinger 2011; Cima 2012;
Department of Health 2009; Hall 2011; Henry 2008; Hoare
2011). Common across current clinical guidelines for the assess-
ment of subjective tinnitus (Fuller 2017), is a recommendation for
the use of written questionnaires to assess tinnitus and its impact
on patients by measuring tinnitus symptom severity (e.g. impact
of tinnitus on quality of life, activities of daily living or sleep),
and a judgement about patients who are experiencing a degree of
psychological distress (including depression or anxiety).
Clinical management strategies include education and advice, re-
laxation therapy, tinnitus retraining therapy (TRT), cognitive be-
havioural therapy (CBT), sound enrichment using ear-level sound
generators or hearing aids, and drug therapies to manage co-mor-
bid symptoms such as sleep difficulties, anxiety or depression (for
example, Department of Health 2009; Tunkel 2014). As yet, no
drug has been approved for tinnitus by a regulatory body (e.g. the
European Medicines Agency or US Food and Drug Administra-
tion).
Pathophysiology
Many people with chronic tinnitus have some degree of measur-
able hearing loss (Ratnayake 2009), and the prevalence of tinnitus
increases with greater hearing loss (Han 2009; Martines 2010).
The varying theories of tinnitus generation involve changes in ei-
ther function or activity of the peripheral (cochlea and auditory
nerve) or central auditory nervous systems (Henry 2005). Theo-
ries involving the peripheral systems include the discordant dam-
age theory, which predicts that the loss of outer hair cell function,
where inner hair cell function is left intact, leads to a release from
inhibition of inner hair cells and aberrant activity (typically hy-
peractivity) in the auditory nerve (Jastreboff 1990). Such aberrant
auditory nerve activity can also have a biochemical basis, resulting
from excitotoxicity or stress-induced enhancement of inner hair
cell glutamate release with upregulation of N-methyl-D-aspartate
(NMDA) receptors (Guitton 2003; Sahley 2001).
In the central auditory system, structures implicated as possible
sites of tinnitus generation include the dorsal cochlear nucleus
(Middleton 2011; Pilati 2012), the inferior colliculus (Dong 2010;
Mulders 2010), and the auditory and non-auditory cortex (dis-
cussed further below). There is a strong rationale that tinnitus is a
direct consequence of maladaptive neuroplastic responses to hear-
ing loss (Moller 2000;Mühlnickel 1998). This process is triggered
by sensory deafferentation and a release from lateral inhibition in
the central auditory system allowing irregular spontaneous hyper-
activity within the central neuronal networks involved in sound
processing (Eggermont 2004; Rauschecker 1999; Seki 2003). As
a consequence of this hyperactivity, a further physiological change
noted in tinnitus patients is increased spontaneous synchronous
activity occurring at the subcortical and cortical level, measurable
using electroencephalography (EEG) ormagnetoencephalography
(MEG) (Dietrich 2001; Tass 2012; Weisz 2005). Another physi-
ological change thought to be involved in tinnitus generation is a
process of functional reorganisation, which amounts to a change
in the response properties of neurons within the primary auditory
cortex to external sounds. This effect is well demonstrated physio-
logically in animal models of hearing loss (Engineer 2011; Noreña
2005). Evidence in humans, however, is limited to behavioural
evidence of cortical reorganisation after hearing loss, demonstrat-
ing improved frequency discrimination ability at the audiomet-
ric edge (Kluk 2006; McDermott 1998; Moore 2009; Thai-Van
2002; Thai-Van 2003), although Buss 1998 did not find this ef-
fect. For comprehensive reviews of these physiological models, see
Adjamian 2009 and Noreña 2011.
It is also proposed that spontaneous hyperactivity could cause an
increase in sensitivity or ’gain’ at the level of the cortex, whereby
neural sensitivity adapts to the reduced sensory inputs, in effect
stabilising mean firing and neural coding efficiency (Noreña 2011;
Schaette 2006; Schaette 2011). Such adaptive changes would be
achieved at the cost of amplifying ’neural noise’ due to the overall
increase in sensitivity, ultimately resulting in the generation of
tinnitus.
Increasingly, non-auditory areas of the brain, particularly areas as-
sociated with emotional processing, are also implicated in bother-
some tinnitus (Rauschecker 2010; Vanneste 2012). Vanneste 2012
describes tinnitus as “an emergent property of multiple parallel
dynamically changing and partially overlapping sub-networks”,
implicating the involvement of many structures of the brain more
associated withmemory and emotional processing in tinnitus gen-
eration. However, identification of the structural components of
individual neural networks responsible for either tinnitus gener-
ation or tinnitus intrusiveness, which are independent of those
for hearing loss, remains open to future research (Melcher 2013).
One further complication in understanding the pathophysiology
of tinnitus is that not all people with hearing loss have tinnitus
and not all people with tinnitus have a clinically significant and
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measurable hearing loss. Other variables, such as the profile of a
person’s hearing loss, may account for differences in their tinnitus
report. For example, König 2006 found that the maximum slope
within audiograms was higher in people with tinnitus than in peo-
ple with hearing loss who do not have tinnitus, despite the ’non-
tinnitus’ group having the greater mean hearing loss. This sug-
gests that a contrast in sensory inputs between regions of normal
and elevated threshold may be more likely to result in tinnitus.
However, this finding is not consistent across the literature (Sereda
2011; Sereda 2015).
Description of the intervention
First registered in 1968, betahistine is an oral drug that, by 2006,
was estimated to have been prescribed to more than 130 million
people worldwide (Jeck-Thole 2006). The indication for taking
betahistine is to treat patients with Ménière’s disease (Electronic
MedicinesCompendium 2015).However,many patients are given
betahistine off-licence to treat idiopathic subjective tinnitus (Hall
2011; McFerran 2018) and vertigo (Murdin 2016), even when
these symptoms are not associated with Ménière’s disease. The
recommended daily dose of betahistine is 24 mg to 48 mg per day
divided into two or three single doses containing 8 mg, 16 mg or
24 mg (Jeck-Thole 2006). Although gastrointestinal side effects
are cited inmany formularies, the rate of adverse effects in patients
taking betahistine is not significantly different from those taking
placebo in comparison studies (Murdin 2016).
Betahistine hydrochloride (or dihydrochloride) is a derivative of
betahistine. Alternative formulations of betahistine include be-
tahistine mesylate (or mesilate), dimesylate and maleate.
How the intervention might work
Betahistine is a weak histamine H1 receptor agonist and a potent
histamine H3 receptor antagonist. One postulated mechanism of
action of the drug is reduction of endolymphatic pressure through
improved microvascular circulation in the stria vascularis of the
cochlea (Martinez 1972). In addition, inhibition of activity in the
vestibular nuclei may contribute to rebalancing neural activity and
expedite the recovery process (Lacour 2007; Timmerman 1994).
Studies have shown that betahistine reaches a peak plasma concen-
tration in about one hour and it has a plasma half-life of approxi-
mately 3.5 hours (ElectronicMedicines Compendium 2015). The
maximal vestibular therapeutic effect will last approximately three
to four hours (Electronic Medicines Compendium 2015).
For Ménière’s disease/syndrome these pharmacological character-
istics are thought to reduce the intensity and duration of vertigo
symptoms in the short term (under three months) and addition-
ally prevent attacks in the longer term (over three months). For
tinnitus, betahistine is thought to work by improving blood flow
to certain areas within the inner ear. However, it is not fully un-
derstand how betahistine actually interacts within the inner ear
to reduce tinnitus symptoms. In some countries, prescription be-
haviour differs according to whether tinnitus is acute (< 3months)
or chronic (≥ 3 months) (Hall 2011). This may reflect a belief
that duration of tinnitus is a modifier of treatment success.
Why it is important to do this review
In England alone there are an estimated ¾ million GP con-
sultations every year where the primary complaint is tinnitus
(El-Shunnar 2011), equating to a major burden on healthcare ser-
vices. A study reported over 100,000 prescriptions for betahis-
tine being filled every month in England (Phillips 2008), and
nearly 10% of general practitioners prescribe betahistine for tin-
nitus. There is a published Cochrane Review of betahistine for
Ménière’s disease (idiopathic) or Ménière’s syndrome (secondary
to established inner ear disorders) (James 2001), and a new pro-
tocol for an update (van Esch 2018). Both examine tinnitus as a
secondary outcome. However, there is no existing Cochrane Re-
view of betahistine for tinnitus as a primary outcome, without the
comorbidities of vertigo and hearing loss. Assessment of the effect
of betahistine in the treatment of subjective idiopathic tinnitus is
therefore warranted.
O B J E C T I V E S
To assess the effects of betahistine in patients with subjective id-
iopathic tinnitus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include studies with the following design characteristics:
• randomised controlled trials, including cluster-randomised
(cross-over trials will be eligible if data from before the cross-over
are extractable, to avoid the potential for a carry-over
phenomenon).
We will exclude studies with the following design characteristics:
• quasi-randomised controlled studies.
We will apply no restrictions on language, year of publication or
publication status.
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Types of participants
Patients of any age with acute or chronic subjective idiopathic
tinnitus. Participants who have received betahistine previously will
be eligible for inclusion.
Types of interventions
Betahistine: any dose regimens or formulations and for any dura-
tion of treatment.
The comparators are placebo, no intervention or education and
information only.
The main comparison will be:
• betahistine versus placebo.
Other possible comparison pairs include:
• betahistine versus no intervention; or
• betahistine versus education and information only.
Concurrent use of other medication or other treatment will be
acceptable if used equally in each group. For example, betahis-
tine with an additional intervention versus placebo with an identi-
cal additional intervention. Where an additional intervention was
used equally in both groups, we will analyse this as a separate com-
parison.
Types of outcome measures
We will analyse the following outcomes in the review, but we will
not use them as a basis for including or excluding studies.
Primary outcomes
• Tinnitus loudness (a change in subjective perception)
measured using either patient-reported instruments (including
visual analogue scales or numerical rating scales) or performance-
based procedures (including Tinnitus Loudness Matching or
Minimum Masking Level).
• Significant adverse effects: upper gastrointestinal
discomfort.
Secondary outcomes
• Tinnitus symptom severity (such as the impact of tinnitus
on quality of life, activities of daily living and sleep), as measured
by the global score on a multi-item tinnitus questionnaire (Table
1). These include:
◦ Tinnitus Functional Index (Meikle 2012);
◦ Tinnitus Handicap Inventory (Newman 1996);
◦ Tinnitus Handicap Questionnaire (Kuk 1990);
◦ Tinnitus Reaction Questionnaire (Wilson 1991);
◦ Tinnitus Questionnaire (Hallam 2009; Hiller 2006);
and
◦ Tinnitus Severity Scale (Sweetow 1990).
• Depressive symptoms or depression as measured by a
validated instrument including the Beck Depression Inventory
(Beck 1988; Beck 1996), the depression scale of the Hospital
Anxiety and Depression Scale (HADS; Zigmond 1983), or the
Hamilton Rating Scale for Depression (Hamilton 1960).
• Anxiety symptoms or generalised anxiety as measured by a
validated instrument including the Beck Anxiety Inventory
(Beck 1988a), the anxiety scale of the HADS (Zigmond 1983),
or the Anxiety Sensitivity Index (Reiss 1986).
• Health-related quality of life as measured by any appropriate
scale including the Short-Form health survey (Hays 1993),
WHOQOL-BREF (Skevington 2004), other WHOQOL
versions and the Health Utilities Index (Furlong 2001).
• Other adverse effects; headache, allergic skin reactions
(pruritis, rashes) and exacerbation of tinnitus.
In addition, we will report the new core outcome for trials of phar-
macological interventions for tinnitus, this being tinnitus intru-
siveness (Fackrell 2017). As there is not yet an agreed definition
of this concept, intrusiveness will be measured by a single item
patient-reported visual analogue scale or numerical rating scale.
Based on the pharmacological properties of the drug described
above, we will assess outcomes as short-term (less than three
months) and long-term (three to six months). We will also con-
sider whether these outcomes are sustained beyond six months.
Search methods for identification of studies
The Cochrane ENT Information Specialist will conduct system-
atic searches for randomised controlled trials and controlled clin-
ical trials. There will be no language, publication year or publica-
tion status restrictions. We may contact original authors for clar-
ification and further data if trial reports are unclear and we will
arrange translations of papers where necessary.
Electronic searches
Published, unpublished and ongoing studies will be identified by
searching the following databases from their inception:
• the Cochrane ENT Register (search to date);
• the Cochrane Central Register of Controlled Trials
(CENTRAL, via the Cochrane Register of Studies (CRS) to
date);
• Ovid MEDLINE(R) Epub Ahead of Print, In-Process &
Other Non-Indexed Citations, Ovid MEDLINE(R) Daily and
Ovid MEDLINE(R) (1946 to date);
• Ovid Embase (1974 to date);
• LILACS (Latin American and Caribbean Health Science
Information database; 1982 to date);
• Web of Knowledge, Web of Science (1945 to date);
• ClinicalTrials.gov, www.clinicaltrials.gov (search via the
Cochrane Register of Studies to date);
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• World Health Organization (WHO) International Clinical
Trials Registry Platform (ICTRP) (search to date).
The subject strategies for databases will be modelled on the search
strategy designed for CENTRAL (Appendix 1). Where appropri-
ate, these will be combined with subject strategy adaptations of
the highly sensitive search strategy designed by Cochrane for iden-
tifying randomised controlled trials and controlled clinical trials
(as described in the Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0, Box 6.4.b. (Handbook 2011)).
Searching other resources
We will scan the reference lists of identified publications for addi-
tional trials and contact trial authors if necessary. In addition, the
Information Specialist will search Ovid MEDLINE to retrieve ex-
isting systematic reviews relevant to this systematic review, so that
we can scan their reference lists for additional trials. The Infor-
mation Specialist will also run non-systematic searches of Google
Scholar to retrieve grey literature and other sources of potential
trials.
We will not perform a separate search for adverse effects of be-
tahistine for tinnitus. We will consider adverse effects described in
the included studies only.
Data collection and analysis
Selection of studies
Three authors (DAH, DM and IS) will independently scan the
initial search results to identify studies that appear to meet the
inclusion criteria. The authors will then review the full-text arti-
cles of the retrieved studies and apply the inclusion criteria inde-
pendently. We will resolve any differences in opinion about which
studies to include in the review by discussion or, failing that, by
consultation with one of the other authors (IW, DS).
Data extraction and management
Three authors (DAH, IW andDS) will independently extract data
from the studies using a purposefully designed data form. We will
extract data so as to allow an intention-to-treat analysis. We will
pilot the data extraction form on a subset of articles and revise it as
indicated before formal data extraction begins.Where necessary or
where insufficient data are provided for the study, we will contact
the authors for further information.
Information to be extracted will include: trial design, country of
recruitment, setting, funding, conflict of interest (any author),
methods or randomisation and blinding, power, number of partic-
ipants, inclusion and exclusion criteria, type of intervention and
control(s), total dose per day (mg),method of administration, con-
comitant treatment, treatment duration, treatment fidelity, type
and duration of follow-up, definition of outcomes and endpoints,
and statistical tests.
Data to be extracted will include: baseline characteristics of par-
ticipants (age, sex, duration of tinnitus, tinnitus symptom sever-
ity, tinnitus loudness estimates, details of co-morbid hearing loss,
anxiety or depression), and details of any attrition or exclusion.
Outcome data to be extracted will include: group mean and stan-
dard deviation at pre- and post-intervention and follow-up, and
results of any statistical tests of between-group comparisons.
With regard to subgroup analysis, we will extract data to allow
grading according to duration of tinnitus and treatment protocol
(dose and duration of drug treatment). If betahistine doses differ
among the intervention groups within a study, we will extract data
on the highest dose and compare this to placebo. Extraction of data
on co-morbidity will involve, for example, depressive symptoms,
generalised anxiety and reduced sound level tolerance).
We will also contact authors where further information is required
that is not contained within the trial publication or in an accessible
database. If not reported or provided by the authors we will es-
timate standard deviations in RevMan 5.3 (RevMan 2014) using
the available data, such as standard errors, confidence intervals, P
values and t values. Where data are only available in graph form,
authors will make and agree numeric estimates.
After independent data extraction, all authors will review the ex-
tracted data for disagreements, and revisit and discuss the relevant
studies as required to reach a final consensus.
Assessment of risk of bias in included studies
Two authors (IW and IS) will undertake assessment of the risk
of bias of the included trials independently, with the following
taken into consideration, as guided by theCochrane Handbook for
Systematic Reviews of Interventions (Handbook 2011):
• sequence generation;
• allocation concealment;
• blinding;
• incomplete outcome data;
• selective outcome reporting; and
• other sources of bias (e.g. lack of an intervention control as
a comparator, improper statistical analysis).
We will use the Cochrane ’Risk of bias’ tool in RevMan 5.3 (
RevMan 2014), which involves describing each of these domains
as reported in the trial and then assigning a judgement about the
adequacy of each entry: ’low’, ’high’ or ’unclear’ risk of bias. We
will resolve differences of opinion by discussion. If no consensus
is reached, we will consult the other authors.
Measures of treatment effect
The primary outcome in this review will be the change in tinnitus
loudness, which is likely to be a continuous variable. For interven-
tion effect measures using continuous data, we plan to calculate
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themean difference (MD) between groups with a 95% confidence
interval (CI), provided that the selected studies used the same scale
of measurement. If different scales having been used, we plan to
calculate the standardised mean difference (SMD) (Cohen’s d ef-
fect size (ES)). A positive effect size indicates that the treatment
group achieved better outcomes than the control group.
We will analyse dichotomous data as risk ratios (RR) with 95%
CIs.
Unit of analysis issues
Cluster-randomised trials
We will include cluster-RCTs with the cluster as the unit of anal-
ysis. For more recent studies, it is most likely that clusters have
been taken into account in the analyses. If not, we will adjust for
the clusters using the methods set out in the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011).
Cross-over trials
For subjective idiopathic tinnitus, it is unlikely that symptom
severity returns to its baseline level after the first treatment period.
Therefore, we will only use data from cross-over trials if data from
before the cross-over can be obtained.
Multi-arm studies
In the event that we find studies with more than two groups (e.g.
two or more active treatments being tested against placebo), we
will establish which of the comparisons are relevant to the system-
atic review and relevant to each of the meta-analyses that we may
implement. As we anticipate that participants will have been in-
cluded in several groups, there is a risk of unit of analysis error. As
a result, we will ensure that participants are included only once per
meta-analysis. Where the study design used independent groups,
we will treat the study as an independent comparison.
Repeated observations on participants
The unit of analysis will be the participant. If studies evaluate the
effect over a longer time period, we may record the results at mul-
tiple time points. To avoid unit of analysis error when combining
study results in a single meta-analysis (and therefore counting the
same participants in more than one comparison), we will define
different outcomes related to the periods of follow-up and we will
perform separate analyses.
Dealing with missing data
Where necessary and where sufficient data from the study are not
provided, we will contact the authors of the study requesting fur-
ther details about missing data and reasons for the incompleteness
of the data. If no useful response is obtained, we will impute data
if we judge the data to be ’missing at random’. If we judge data to
be ’missing not at random’, the missing data may affect the overall
results; we will therefore not impute data. In the latter case, we
will conduct sensitivity analysis with different assumptions.
We will be alert to potential mislabelling or non-identification of
standard errors and standard deviations. Ourmethods for imputa-
tion will be according to chapter 7.7.3 of the Cochrane Handbook
for Systematic Reviews of Interventions (Handbook 2011).
If data are missing, we will use available case analysis using all data
(as reported) for all randomised patients available at the end of
the study/time point of interest, regardless of the actual treatment
received. We will consider the quality of outcome assessment as a
study limitation (GRADE) and not as a stratifying factor.
Assessment of heterogeneity
We will determine whether the selected studies suffer from clini-
cal, statistical and methodological heterogeneity.We will quantify
statistical heterogeneity using the I2 statistic and the Chi2 test.
With respect to the I2 statistic, an approximate guide to interpre-
tation is provided in theCochrane Handbook for Systematic Reviews
of Interventions (Handbook 2011). If the I2 value is 50% or higher,
the data can be considered to suffer from substantial or consider-
able heterogeneity. For the Chi2 test, we will use the indicator that
where the Chi2 is greater than the degrees of freedom (where the
degrees of freedom are the number of studies K minus 1), then
heterogeneity is likely to be present. We will consider heterogene-
ity to be statistically significant if the P value is less than 0.10.
Subsequently, we will perform the meta-analysis using fixed-effect
(in the absence of heterogeneity) and random-effects modelling
(in the presence of heterogeneity). If the level of heterogeneity re-
mains unclear we will seek statistical advice.
Assessment of reporting biases
We will search for and request study protocols for the included
studies and, where available, we will evaluate whether there is
evidence of selective reporting. If a meta-analysis contains at least
10 studies, we will assess publication bias using a funnel plot and
Egger’s test.
Data synthesis
If more than one study is identified for a given option, and if com-
bining studies is appropriate, we will use RevMan 5.3 to perform
meta-analyses (RevMan 2014). We will pool data from RCTs us-
ing a fixed-effect model, except when heterogeneity is found. We
will pool continuous data using the SMD measure, if more than
one instrument is used to measure the same outcome.
We will consider the psychometric properties of the outcome in-
struments with regard to their suitability for pooling. For meta-
analyses of the primary outcome (tinnitus loudness), whenever
studies report outcomes measured by more than one instrument,
data will be included only when those instruments are known to
measure the same underlying construct of tinnitus loudness (high
convergent validity) and show a similar direction of treatment-
related effect. We will take the same approach for secondary out-
comes.
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Subgroup analysis and investigation of heterogeneity
If sufficient data are available, we will carry out subgroup analyses.
This will be restricted to a very small number of subgroups and we
will perform a significance test for interaction with the treatment
effect.We will clearly specify the boundaries for defining inclusion
and exclusion in advance, and for age we will consider whether
specifying a cut-off of 16 or 18 years has an effect on the findings.
The planned subgroups are defined by:
• age (children < 16 or 18 years and adults ≥ 16 or 18 years);
• duration of tinnitus (acute ≤ 3 months and chronic > 3
months);
• dose of betahistine administered (minimum daily dose of 8
mg to a maximum of 148 mg);
• additional interventions (betahistine with and without an
additional intervention).
Sensitivity analysis
We will conduct a sensitivity analysis by excluding those studies
with a high risk of bias, thereby checking the robustness of the
conclusion from the studies included in the meta-analysis. In ad-
dition, we will use sensitivity analyses for studies in which data
were imputed.
GRADE and ’Summary of findings’ table
Two independent authors (IW and IS) will use the GRADE ap-
proach to rate the overall quality of evidence using GRADEpro
GDT ( https://gradepro.org/). The quality of evidence reflects the
extent to which we are confident that an estimate of effect is cor-
rect and we will apply this in the interpretation of results. There
are four possible ratings: high, moderate, low and very low. A rat-
ing of high quality of evidence implies that we are confident in
our estimate of effect and that further research is very unlikely to
change our confidence in the estimate of effect. A rating of very
low quality implies that any estimate of effect obtained is very
uncertain.
TheGRADE approach rates evidence fromRCTs that do not have
serious limitations as high quality. However, several factors can
lead to the downgrading of the evidence to moderate, low or very
low. The degree of downgrading is determined by the seriousness
of these factors:
• study limitations (risk of bias);
• inconsistency;
• indirectness of evidence;
• imprecision; and
• publication bias.
We will include a ’Summary of findings’ table, constructed ac-
cording to the recommendations described in Chapter 11 of
the Cochrane Handbook for Systematic Reviews of Interventions
(Handbook 2011), for the following comparison(s):
• betahistine versus placebo;
• betahistine versus no intervention; and
• betahistine versus education and information only.
We will include the following outcomes in the ’Summary of find-
ings’ table:
• tinnitus loudness;
• significant adverse events (tinnitus exacerbation);
• tinnitus symptom severity;
• other adverse effects (upper gastrointestinal discomfort,
headache and allergic skin reactions);
• depressive symptoms; and
• symptoms of generalised anxiety.
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A D D I T I O N A L T A B L E S
Table 1. Examples of questionnaires measuring tinnitus symptom severity
Measurement instrument (author, year) Number of items and subscales Internal consistency (Cronbach’s alpha for the
global score)
Tinnitus Functional Index (Meikle 2012) 25 items, 8 subscales 0.97
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Table 1. Examples of questionnaires measuring tinnitus symptom severity (Continued)
Tinnitus Handicap Inventory (Newman
1996)
25 items, 3 subscales 0.93
Tinnitus Handicap Questionnaire (Kuk
1990)
27 items, 3 subscales 0.94
Tinnitus Reaction Questionnaire (Wilson
1991)
26 items 0.96
Tinnitus Questionnaire, English version (
Hallam 2009)
52 items, 5 subscales 0.94
Tinnitus Questionnaire, German version (
Hiller 2006)
52 items, 6 subscales 0.93
Tinnitus Severity Scale (Sweetow 1990) 15 items Not reported
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
1 MESH DESCRIPTOR Tinnitus EXPLODE ALL AND CENTRAL:TARGET
2 (tinnit*):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
3 #1 OR #2
4 MESH DESCRIPTOR betahistine EXPLODE ALL AND CENTRAL:TARGET
5 (betahistin* or serc or betaserc):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
6 AEQUAMEN or BETASERK or BEATSERKA or EXTOVYL or FIDIUM or LECTIL or LOBIONE or MEGINALISK or
MELOPAT or MENIACE or MERISLON or MICROSER or RIBRAIN or VASOMOTAL AND CENTRAL:TARGET
7 ((BY next vertin)):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
8 (Betavert or vertigon or pt9 or “pt 9”):AB,EH,KW,KY,MC,MH,TI,TO AND CENTRAL:TARGET
9 #4 OR #5 OR #6 OR #7 OR #8
10 #3 AND #9
12Betahistine for tinnitus (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C O N T R I B U T I O N S O F A U T H O R S
DAHconceived the study and drafted the protocol. All authors contributed to the design and critically revised the protocol for important
intellectual content.
Planned author contributions to the full review:
The Cochrane ENT Information Specialist will develop and run the search strategy.
DAH will obtain copies of studies with assistance from the NIHR Nottingham Biomedical Research Centre.
DAH, DM and IS will be responsible for selection of studies.
DAH, IW and DS will be responsible for data extraction.
IW and IS will be responsible for assessing risk of bias.
IW will enter data into RevMan.
IW, DS and IS will conduct and interpret the analysis.
IW, IS and DAH will draft the final review.
DAH, DS and IS will be responsible for updating the review.
D E C L A R A T I O N S O F I N T E R E S T
Deborah A Hall: DAH is an NIHR Senior Investigator and Section Editor for the journal Hearing Research, Elsevier. She leads the
Core Outcome Measures in Tinnitus (COMiT) initiative whose work is currently supported by the European Union’s Horizon 2020
research and innovation programme under the Marie Sk odowska-Curie grant agreement No 764604 and the NIHR Nottingham
Biomedical Research Centre.
Inge Wegner: none known.
Adriana Leni Smit: none known.
Don McFerran: receives royalties for writing books on tinnitus has received consultancy honoraria from GlaxoSmithKline, Autifony
and Otonomy.
Inge Stegeman: none known.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
13Betahistine for tinnitus (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
External sources
• National Institute for Health Research, UK.
Infrastructure funding for Cochrane ENT
• NIHR Senior Investigator award, UK.
14Betahistine for tinnitus (Protocol)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
